BioCentury | Dec 15, 2014
Company News

Modern Biosciences, J&J deal

...Modern Biosciences and Johnson & Johnson’s Janssen Biotech Inc. subsidiary partnered to develop Modern Biosciences’ small molecules...
...to the products, but Modern Biosciences declined to disclose when the pharma may exercise the option. Modern Biosciences...
...upfront payment and regulatory and commercialization milestones. The biotech is also eligible to receive royalties. Modern Biosciences’...
BioCentury | Nov 12, 2012
Company News

Medical Research Council pharmaceuticals news

...U.K.) for its meningococcal vaccine program; Immunocore Ltd. (Oxfordshire, U.K.) for its prostate cancer program; Modern Biosciences...
BioCentury | Jan 7, 2010
Targets & Mechanisms

HCV cache: the list

...Pfizer Inc. Marketed to prevent disseminated Mycobacterium avium complex (MAC) disease Rimcazole s-1 Receptor agonist Modern Biosciences...
BioCentury | Apr 21, 2008
Clinical News

Rimcazole: Phase Ia started

...licensed the compound from the University of Dundee last year (see BioCentury, Aug. 6, 2007). Modern Biosciences...
BioCentury | Feb 11, 2008
Company News

Modern Biosciences management update

Modern Biosciences plc , London, U.K. Business: Musculoskeletal, Autoimmune, Cancer Hired: Kevin Moulder as head of development, formerly VP of development at GlaxoSmithKline plc 's Domantis Ltd. unit WIR Staff autoimmune cancer Musculoskeletal...
BioCentury | Jan 14, 2008
Company News

Modern Biosciences management update

Modern Biosciences plc , London, U.K. Business: Musculoskeletal, Autoimmune, Cancer Hired: William Turner as finance director, formerly group financial controller at IP Group plc WIR Staff autoimmune cancer Musculoskeletal...
BioCentury | Oct 22, 2007
Company News

Modern Biosciences, University of Aberdeen deal

...The university granted Modern Biosciences an exclusive, worldwide license to preclinical compounds to treat osteoporosis, rheumatoid arthritis...
...DMARDs that inhibit multiple undisclosed signaling pathways. The partners will share revenues from resulting compounds. Modern Biosciences...
...begin Phase I trials to treat RA within two years. Further terms were not disclosed. Modern Biosciences...
BioCentury | Sep 10, 2007
Company News

IP Group plc board of directors update

...Group plc (LSE:IPO), London, U.K. Business: Cancer Appointed: Clive Dix as non-executive chairman of IPO's Modern Biosciences...
BioCentury | Aug 6, 2007
Company News

Modern Biosciences, University of Dundee deal

...The university granted Modern Biosciences an exclusive worldwide license to develop rimcazole to treat cancer. The company...
...Phase Ib testing next year. The partners will share revenue. Further terms were not disclosed. Modern Biosciences...
Items per page:
1 - 9 of 9
BioCentury | Dec 15, 2014
Company News

Modern Biosciences, J&J deal

...Modern Biosciences and Johnson & Johnson’s Janssen Biotech Inc. subsidiary partnered to develop Modern Biosciences’ small molecules...
...to the products, but Modern Biosciences declined to disclose when the pharma may exercise the option. Modern Biosciences...
...upfront payment and regulatory and commercialization milestones. The biotech is also eligible to receive royalties. Modern Biosciences’...
BioCentury | Nov 12, 2012
Company News

Medical Research Council pharmaceuticals news

...U.K.) for its meningococcal vaccine program; Immunocore Ltd. (Oxfordshire, U.K.) for its prostate cancer program; Modern Biosciences...
BioCentury | Jan 7, 2010
Targets & Mechanisms

HCV cache: the list

...Pfizer Inc. Marketed to prevent disseminated Mycobacterium avium complex (MAC) disease Rimcazole s-1 Receptor agonist Modern Biosciences...
BioCentury | Apr 21, 2008
Clinical News

Rimcazole: Phase Ia started

...licensed the compound from the University of Dundee last year (see BioCentury, Aug. 6, 2007). Modern Biosciences...
BioCentury | Feb 11, 2008
Company News

Modern Biosciences management update

Modern Biosciences plc , London, U.K. Business: Musculoskeletal, Autoimmune, Cancer Hired: Kevin Moulder as head of development, formerly VP of development at GlaxoSmithKline plc 's Domantis Ltd. unit WIR Staff autoimmune cancer Musculoskeletal...
BioCentury | Jan 14, 2008
Company News

Modern Biosciences management update

Modern Biosciences plc , London, U.K. Business: Musculoskeletal, Autoimmune, Cancer Hired: William Turner as finance director, formerly group financial controller at IP Group plc WIR Staff autoimmune cancer Musculoskeletal...
BioCentury | Oct 22, 2007
Company News

Modern Biosciences, University of Aberdeen deal

...The university granted Modern Biosciences an exclusive, worldwide license to preclinical compounds to treat osteoporosis, rheumatoid arthritis...
...DMARDs that inhibit multiple undisclosed signaling pathways. The partners will share revenues from resulting compounds. Modern Biosciences...
...begin Phase I trials to treat RA within two years. Further terms were not disclosed. Modern Biosciences...
BioCentury | Sep 10, 2007
Company News

IP Group plc board of directors update

...Group plc (LSE:IPO), London, U.K. Business: Cancer Appointed: Clive Dix as non-executive chairman of IPO's Modern Biosciences...
BioCentury | Aug 6, 2007
Company News

Modern Biosciences, University of Dundee deal

...The university granted Modern Biosciences an exclusive worldwide license to develop rimcazole to treat cancer. The company...
...Phase Ib testing next year. The partners will share revenue. Further terms were not disclosed. Modern Biosciences...
Items per page:
1 - 9 of 9